Eisenach J C, Gebhart G F
Department of Anesthesia, Wake Forest University Medical Center, Winston-Salem, North Carolina 27157-1009, USA.
Anesthesiology. 1995 Nov;83(5):1046-54. doi: 10.1097/00000542-199511000-00018.
Amitriptyline and other tricyclic antidepressants exhibit high affinity binding to N-methyl-D-aspartate (NMDA) receptors in vitro and inhibit NMDA receptor activation-induced neuroplasticity in hippocampal slices. Because spinal NMDA receptor activation is believed to be central to generation and maintenance of hyperalgesic pain, the purpose of this study was to test whether intrathecal amitriptyline reduced inflammation-induced hyperalgesia in the rat.
Rats were prepared with chronic lumbar intrathecal and femoral intravenous catheters and nociceptive threshold was assessed by hind paw withdrawal to a radiant heat stimulus. Rats received an injection of carrageenin in one hind paw followed by thermal paw withdrawal testing 3 hr later and intrathecal amitriptyline and/or intravenous morphine injection. In other rats, intrathecal NMDA injection was preceded by either intrathecal saline or 60 micrograms amitriptyline.
Intrathecal amitriptyline reversed thermal hyperalgesia in a dose-dependent manner, but had no effect on withdrawal latency of the contralateral, noninjected paw. Intrathecal phentolamine plus methysergide did not alter amitriptyline's effect, except at the lowest dose. Intravenous morphine increased paw withdrawal latency in both inflamed and control paws in a dose-dependent fashion, and morphine interacted additively with intrathecal amitriptyline to reverse hyperalgesia. Thermal hyperalgesia induced by NMDA was completely antagonized by intrathecal amitriptyline.
Amitriptyline and other tricyclic antidepressants have been demonstrated to exhibit modest activity against clinical neuropathic pain after systemic administration. These data suggest that more profound pain relief might be obtained by intrathecal administration. Amitriptyline reverses hyperalgesia in rats by a mechanism unrelated to monoamine reuptake inhibition, and likely due to NMDA receptor antagonism.
阿米替林和其他三环类抗抑郁药在体外对N-甲基-D-天冬氨酸(NMDA)受体表现出高亲和力结合,并抑制海马切片中NMDA受体激活诱导的神经可塑性。由于脊髓NMDA受体激活被认为是痛觉过敏疼痛产生和维持的核心,本研究的目的是测试鞘内注射阿米替林是否能减轻大鼠炎症诱导的痛觉过敏。
给大鼠植入慢性腰段鞘内和股静脉导管,通过后爪对热辐射刺激的退缩来评估伤害性感受阈值。给大鼠一侧后爪注射角叉菜胶,3小时后进行热爪退缩测试,并鞘内注射阿米替林和/或静脉注射吗啡。在其他大鼠中,鞘内注射NMDA之前先鞘内注射生理盐水或60微克阿米替林。
鞘内注射阿米替林以剂量依赖性方式逆转热痛觉过敏,但对未注射的对侧爪的退缩潜伏期没有影响。鞘内注射酚妥拉明加麦角新碱除了在最低剂量外,并未改变阿米替林的作用。静脉注射吗啡以剂量依赖性方式增加炎症爪和对照爪的爪退缩潜伏期,且吗啡与鞘内注射的阿米替林相加作用以逆转痛觉过敏。鞘内注射阿米替林完全拮抗NMDA诱导的热痛觉过敏。
阿米替林和其他三环类抗抑郁药已被证明在全身给药后对临床神经性疼痛表现出适度活性。这些数据表明,鞘内给药可能会获得更显著的疼痛缓解。阿米替林通过一种与单胺再摄取抑制无关的机制逆转大鼠的痛觉过敏,可能是由于NMDA受体拮抗作用。